Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.

J Liver Cancer · 2026 · PMC13062625 · PMID 41781152

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

a strong trendP =0.052so close (0.05 < p ≤ 0.1)

did not reach statistical significanceno p-value reported

5.3 months for sorafenib, a strong trend ( P =0.052) that did not reach statistical significance.

also in 3,373 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.